A paysign A paysign

©2020 Paysign, Inc. All rights reserved. Paysign[®] is a registered trademark.



Important Notices

Forward-Looking Statements and Use of Non-GAAP Financial Information

This presentation may include "forward-looking statements." To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Paysign, Inc.'s ("Company") business plans, results of operations, the impact of Covid-19, returns on equity, expected gross margins, markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes."

Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in our 2019 Form 10-K.

Forward-looking statements speak only as of the date of the document in which they are contained, and the Company does not undertake any duty to update any forward-looking statements except as may be required by law. This presentation also includes adjusted EBITDA, a non-GAAP financial measure, that is not prepared in accordance with, nor an alternative to, financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). In addition, adjusted EBITDA is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly-titled measures presented by other companies.



Presentation Overview

- Company Overview
- Investment Highlights
- Company Milestones
- Growth Strategy and Markets
- Technology Platform
- Competitive Advantages
- Business Drivers
- Investments by the Numbers
- Financial Highlights
- Leadership and Directors





Paysign® A Reliable Payments Partner

Paysign provides innovative payment products designed to **reward** consumers, clients, and employees, delivers patient affordability solutions to the pharmaceutical industry, and offers a mobile-first digital banking solution to businesses and their consumers.

Paysign is dedicated to creating payment solutions that help our clients lower their administrative costs, streamline operations, and drive revenue.





Company Overview

- Paysign was incorporated in 2001 and is headquartered in Henderson, Nevada.
- We are an experienced and trusted provider of prepaid debit card payment solutions and integrated payment processing with millions of prepaid debit cards.
- We design and develop custom prepaid and debit card payment solutions, both physical and digital, for industries such as healthcare, pharmaceutical, corporate incentive, retail, hospitality, and many others.
- As a full-service partner, we manage programs for many of the world's largest pharmaceutical manufacturers and corporations, offering card payment solutions designed to maximize customer acquisition, retention, and adherence.
- Our customizable solutions offer significant cost savings while improving brand recognition and customer loyalty.



Financial Snapshot

Stock Price (11/27/20)	\$5.02
52 Week Range	\$3.63 - \$10.98
Market Cap	\$250.2M
Shares Outstanding	49.8M
TTM Revenue	\$26.6M
Cash	\$7.5M/ \$55.5M ¹
Debt	\$0
	1 Total including restricted o

¹ Total including restricted cash






Investment Highlights

Revenue Growth

Fast-growing, high-margin, profitable business with predictable recurring revenues

Products and Solution

Large market opportunity in corporate incentives, consumer incentives, and digital bank account with high barriers to entry



Financials Strong cashflow and no debt



Leadership

Highly accomplished and experienced management team and board

Technology

Leading proprietary cloud-based payments platform

Service and Delivery

Superior client retention and quality of service

Company Milestones

2006

Company begins operating as 3PEA International, Inc.

2011

first plasma

2001

Company is founded as 3PEA Technologies, Inc. in Henderson, NV.

2007

The company's first pharmaceutical client is signed.



2018

May – Formation of experienced Board of Directors.

Aug – The company is listed on NASDAQ, has more than 2.2M cardholders and \$621M loaded onto cards.

2020

The company launches the Patient Affordability product line.

2017

The company reports more than 1.5M cardholders and \$409M loaded onto cards.

2019

3PEA International, Inc. is rebranded as Paysign, Inc. and PAYS ticker created.

This year saw continued growth with the launch of the Paysign Premier Digital Bank Account, 3M cardholders and \$882M loaded onto cards.

The company's client is signed.



Growth Strategy Driving Profitable Growth



Grow

Protect and grow core plasma business

Partner with pharma industry by providing copay assistance programs, buy and bill programs and pharmaceutical rebates

Diversify

New products: Paysign Premier Paysign Rewards Paysign Business

New industry segments

New geographies



8

Build

New payment capabilities and product features

> Acquire new business lines

Deliver


Deliver operational excellence

Make data-driven decisions with comprehensive data analytics capabilities



2023 U.S. Open-Loop Prepaid Market Forecast

Total Prepaid Market






Market Segments Where We Operate

Paysign **Products**

Providing Donor Compensation Solutions Since 2011

Paysign Processed Over 17M Donor Compensation Payments in 2019

US Plasma Centers




We delivered card programs to our first plasma industry client in 2011. This client remains Paysign's largest client to date. The company now has over 12 plasma clients and operates in over 290 card program centers.

1 https://www.donatingplasma.org/donation/find-a-donor-center

2 Plasma Protein Therapeutics Association, Total Collection in U.S. https://www.pptaglobal.org/images/Data/Plasma Collection/Total Yearly Collections 2008-2019.pdf





Patient Affordability Solutions Helping Patients Offset Their Out-of-Pocket Rx Costs

Paysign's **Patient Affordability Solutions** help pharmaceutical brands deploy coupon programs that are used by commercially insured patients to offset their out-of-pocket (OOP) costs.

Copay Solutions – Pharmacy-based solution which acts as a voucher funding the full cost of a drug or as a secondary payor, paying all or part of a patients OOP responsibility.

Medical Benefit Solutions – This solution works like our copay programs but utilizes the medical billing and payment systems of hospitals, doctor's offices, and providers.

Buy + Bill Solutions – For certain therapies, providers choose to stock and dispense the product in-office. Once a patient is registered for the program we will deliver a physical or digital open-loop prepaid card to the treatment location to assist in the payment of the therapy.

Centralized Billing Solutions – This suite of services enables brands to address affordability concerns beyond the cost of the drug and assists in getting patients to the therapy, covering travel, lodging, and per diem costs.




19%

Percent of commercially insured patients on branded medications that used coupons to reduce their out-of-pocket costs in 2018

OOP Costs Offset By Coupons¹



As out-of-pocket costs have risen, coupons for commercially insured patients have reached an all-time high in 2018.



1 IQVIA Institute for Human Data Science, "Medicines Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023" (May 2019)

A Full-Service Provider

Cardholder Portals and Mobile Apps

Self-Service Partner Portal **Client** AP Solut

Full-service, end-to-end, card-based solutions from initial program design to on

Core Tec

Paysign proprietary card management and au of 99.999%. Supports fully customized p

Support

Card Networks

Visa Mastercard Discover Pulse Allpoint

MoneyPass

Identity Services

LexisNexis® **IDology**® Envestnet® | Yodlee®



I-Based ions In-House, Bilin Customer C	ngual Cho	aud and argeback nagement
ement Services as both a processor and progra going post-launch client suppor	-	
hnology thorization platform with a syste hysical or digital cards and acc		⇔paysign 4000 1234 ₩₩ 1
Services		John H. Smith
Card Production	Comp	oliance
MT&L Perfect Plastics	SSAE18/SC	PCI-DSS DC 1 Type II Audits



Competitive Advantages

paysign



End-to-End Solutions: Paysign is both the processor and program manager



Direct Connection: Paysign connects directly to the Fed f backend processing, dramatically increasing our uptime



Client-Tailored Services: Paysign creates customized, innovative payment solutions unique to the client's needs



Superior Service: Paysign offers in-house, bilingual customer service



Timely Solution Delivery: Paysign is expedient and nimb when creating solutions, and is dedicated to providing clie with programs and changes in the shortest possible time



Extended Services: Paysign is proud to offer a suite of extended, value-added services





or		
le		
nts		
frame		

The Competition

Limited account management services. Clients are asked to choose between a processor or a program manager

More downtime due to third-party processing connections

Sporadic, hard-to-reach customer service


Cost-prohibitive customization and long lead times

Slow and expensive integration

Limited value-added services


Business Drivers

Cumulative **Cards Issued 5.3M**



Cumulative Cardholders

4.0M






Investment by the Numbers





Revenue by Industry



Revenue Drivers

Cardholder Fees









Growth &

Diversification

2016-2019

CAGR with expansion

into Pharma

45%

 Pharma, \$1,240,665 Other, \$658,261 	Total Revenue \$26.6M
\$7,372,990 • Other, \$298,734	\$34.7M
Pharma, \$366,442 Other, \$25,410	\$23.4M
	\$15.2M
a 🗖 Pharma 🔳 Other	\$10.4M
nterchange Management Fees	Other Fees

Financial Highlights

Income Statement Summary

Revenue and Reconciliation of Net Income to Adjusted EBITDA

Revenues

Net Income (loss)

Income tax expense (ben

Interest income

Depreciation and amortiz

EBITDA

Stock-based compensation

Disposal/ Impairment of

Adjusted EBITDA



2020 TTM 2019 2018 2017 istand \$26,631,972 \$334,666,653 \$23,423,675 \$15,234,091 istand (2,946,625) 7,454,319 2,588,054 1,791,141 inefit) (3,125,783) (909,976) - 6,000 ization 1,982,005 1,483,140 (139,738) 7,663,763 ization 1,982,005 1,483,140 1,089,521 876,191 ization 1,982,005 1,483,140 1,089,521 876,191 ization 1,982,005 1,483,140 1,089,521 876,191 isation 1,982,005 1,483,140 1,089,521 876,191 isation 1,982,005 1,483,140 1,089,521 876,191 isan 2,786,533 2,528,613 1,366,944 308,696 f assets 425,312 2,974,425 (1,032,497) \$10,114,980 4,904,781 2,974,425					
Image: constraint of constraints of		2020 TTM	2019	2018	2017
nefit) (3,125,783) (909,976) - 6,000 (153,939) (441,116) (139,738) (7,603) ization 1,982,005 1,483,140 1,089,521 876,191 (4,244,342) 7,586,367 3,537,837 2,665,729 ion 2,786,533 2,528,613 1,366,944 308,696		\$26,631,972	\$34,666,653	\$23,423,675	\$15,234,091
(153,939) (441,116) (139,738) (7,603) ization 1,982,005 1,483,140 1,089,521 876,191 (4,244,342) 7,586,367 3,537,837 2,665,729 cion 2,786,533 2,528,613 1,366,944 308,696 f assets 425,312		(2,946,625)	7,454,319	2,588,054	1,791,141
ization 1,982,005 1,483,140 1,089,521 876,191 (4,244,342) 7,586,367 3,537,837 2,665,729 tion 2,786,533 2,528,613 1,366,944 308,696 f assets 425,312	nefit)	(3,125,783)	(909 <i>,</i> 976)	-	6,000
Image: constraint of the constraint		(153,939)	(441 <i>,</i> 116)	(139,738)	(7,603
tion 2,786,533 2,528,613 1,366,944 308,696	ization	1,982,005	1,483,140	1,089,521	876,191
fassets 425,312		(4,244,342)	7,586,367	3,537,837	2,665,729
	ion	2,786,533	2,528,613	1,366,944	308,696
(1,032,497) \$10,114,980 4,904,781 2,974,425	fassets	425,312			
		(1,032,497)	\$10,114,980	4,904,781	2,974,425



Leadership Team




Mark Newcomer President, CEO, and Vice Chairman

Mark Newcomer has been the face, voice, and backbone of Paysign since 2006. For nearly 20 years, Newcomer has also served as chairman and CEO of 3PEA Technologies, Inc. (a subsidiary of Paysign Inc.), the payment solutions company he co-founded in 2001 with Dan Spence. Today, Newcomer continues to expertly guide the company's growth through technology investments, acquisitions, new product lines, and strategic partnerships.




Dan Spence Co-Founder, Director, and EVP

Dan Spence has been a driving force at Paysign since 2006. Spence has served in senior IT roles for over 30 years, with more than a decade of experience in payment processing.



Robert Strobo General Counsel

Strobo joined Paysign in 2018. He served as deputy general counsel for Republic Bank & Trust, and has specialized experience with prepaid card issuance and nontraditional banking.



Matt Turner Vice President, Patient Affordability Services

Turner joined Paysign in 2019. Prior to that, he served as director of product management, patient affordability and pharmacy at TrialCard.





Mark Attinger Chief Financial Officer

Attinger joined Paysign in 2018, bringing 30 years of leadership, finance, and operations experience to the organization, including 12 years with American Express.



Joan Herman Chief Operating Officer and Director

Herman joined Paysign in 2017, bringing nearly 30 years of experience in the payments industry to the team.



Matt Lanford Chief Product Officer

Lanford joined Paysign in 2019. He has more than 30 years of experience in the payments industry. Before joining, he was the SVP/GM of the financial services division of InComm.



Eric Trudeau Chief Compliance Officer

Trudeau joined Paysign in 2018. Prior to that he held positions at Global Cash Card, Inc., Sunrise Banks, and Meta Payment Systems.



David Hooker Chief Technology Officer

Hooker joined Paysign in 2020. Prior to that he held senior technology positions at Cisco, Ganart Technologies, and NantHealth.



Alicia Ches Director of Marketing

Ches joined Paysign in 2020 and brings more than 10 years of experience in the payments industry. Before joining Paysign, she was director of marketing for Shift4 Payments.



Independent Directors

Dan Henry Chairman of the Board, Compensation Committee Chair

Quinn Williams

Director, Nominating **Committee Chair**

Bruce A. Mina

Director, Audit Committee Chair

Dennis Triplett

Director

- and venture capital transaction
- and board member of Swensen's Inc.
- •



Current CEO and president of Green Dot Corporation (NYSE: GDOT), current market cap \$2.78 Former CEO of NetSpend (2008-2013); grew annual revenue from \$129M to \$351M, with over 2.4M cardholder accounts; NetSpend acquired by Total System Services: (NYSE: TSS) for \$1.4B Co-founder, former president, and COO and director at Euronet Worldwide (NASDAQ: EEFT)

30+ years of legal experience focusing on mergers and acquisitions, public and private securities offerings,

Serves as corporate counsel for numerous public and private companies and was formerly general counsel

Mr. Williams is a shareholder with Greenberg Traurig LLP and admitted to the Bar in New York and Arizona


30+ years of experience as a certified public accountant

Founder and managing member of Mina Llano Higgins Group, LLP

Former CFO of Coal Brick Oven Pizzeria, Inc.

Currently CFO for Academy of Aviation in Long Island, NY

35+ years in the banking industry including serving as the President and CEO of two banks in the Midwest Former CEO of Healthcare Services at UMB Bank, N.A, a leading provider of healthcare payment solutions including health savings accounts (HSAs), healthcare spending accounts, and payments technology







2615 St Rose Parkway Henderson, NV 89052 **United States**





19

©2020 Paysign, Inc. All rights reserved.



Thank you!

Jim McCroy Investor Relations <u>ir@paysign.com</u>



Office: 702.453.2221 Fax: 702.453.2223 Direct: 702.749.7269